/EDIT

EDIT Stock - Editas Medicine, Inc.

Q: What is the analyst price target for EDIT?

Analyst price target information is not currently available for EDIT.

Q: What is EDIT's market cap?

Market capitalization information is not currently available for EDIT.

Healthcare|Biotechnology|NASDAQ

$2.09-1.88%

$0.04 (-1.88%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+851.7%upside

Target: $19.89

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EDIT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.16

52W High$4.54

52W Low$0.91

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$32.31M	$78.12M	$19.71M	$25.54M	$90.73M
Gross Profit	$32.31M	$72.06M	$13.38M	$20.49M	$-67,264,000
Gross Margin	100.0%	92.2%	67.9%	80.2%	-74.1%
Operating Income	$-251,152,000	$-169,181,000	$-225,950,000	$-193,146,000	$-134,840,000
Net Income	$-237,093,000	$-153,219,000	$-220,432,000	$-192,502,000	$-115,976,000
Net Margin	-733.7%	-196.1%	-1118.3%	-753.6%	-127.8%
EPS	$-2.88	$-2.02	$-3.21	$-2.85	$-1.98

Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Visit Website

Earnings History & Surprises

EDIT

Beat Rate

72%

Last 18 quarters

Avg Surprise

+5.2%

EPS vs Estimate

Beats / Misses

13/5

Last 12 quarters

Latest EPS

$-0.28

Q4 2025

EPS Surprise History

Q1 24

+55.8%

$-0.23vs$-0.52

Q2 24

-20.6%

$-0.76vs$-0.63

Q3 24

-18.8%

$-0.82vs$-0.69

Q4 24

+1.3%

$-0.75vs$-0.76

Q1 25

-41.0%

$-0.55vs$-0.39

Q2 25

+15.7%

$-0.43vs$-0.51

Q3 25

-53.7%

$-0.63vs$-0.41

Q4 25

+26.3%

$-0.28vs$-0.38

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Mar 4, 2026	$-0.27	—	—	—
Q4 2025	Nov 10, 2025	$-0.38	$-0.28	+26.3%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.41	$-0.63	-53.7%	✗ MISS
Q2 2025	May 12, 2025	$-0.51	$-0.43	+15.7%	✓ BEAT
Q1 2025	Mar 5, 2025	$-0.39	$-0.55	-41.0%	✗ MISS
Q4 2024	Nov 4, 2024	$-0.76	$-0.75	+1.3%	✓ BEAT
Q3 2024	Aug 7, 2024	$-0.69	$-0.82	-18.8%	✗ MISS
Q2 2024	May 8, 2024	$-0.63	$-0.76	-20.6%	✗ MISS
Q1 2024	Feb 28, 2024	$-0.52	$-0.23	+55.8%	✓ BEAT
Q4 2023	Nov 3, 2023	$-0.64	$-0.55	+14.1%	✓ BEAT
Q3 2023	Aug 2, 2023	$-0.76	$-0.56	+26.3%	✓ BEAT
Q2 2023	May 5, 2023	$-0.79	$-0.71	+10.1%	✓ BEAT
Q1 2023	Feb 22, 2023	$-0.84	$-0.88	-4.8%	✗ MISS
Q4 2022	Nov 2, 2022	$-0.87	$-0.81	+6.9%	✓ BEAT
Q3 2022	Aug 3, 2022	$-0.84	$-0.78	+7.1%	✓ BEAT
Q2 2022	May 4, 2022	$-0.81	$-0.74	+8.6%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.78	$-0.61	+21.8%	✓ BEAT
Q4 2021	Nov 8, 2021	$-0.86	$-0.57	+33.7%	✓ BEAT
Q3 2021	Aug 4, 2021	$-0.85	$-0.81	+4.7%	✓ BEAT

Frequently Asked Questions about EDIT

What is EDIT's current stock price?

Editas Medicine, Inc. (EDIT) is currently trading at $2.09 per share. The stock has moved -1.88% today.

What is the analyst price target for EDIT?

The average analyst price target for EDIT is $19.89, based on 1 analyst.

What sector is Editas Medicine, Inc. in?

Editas Medicine, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is EDIT's market cap?

Editas Medicine, Inc. has a market capitalization of $0.18 billion, making it a small-cap company.

Does EDIT pay dividends?

No, Editas Medicine, Inc. does not currently pay a dividend to shareholders.